leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PHARMA REPORT

rss_Pharma.jpg...see all
Global Asthma & COPD Therapies Market 2017-2027

Global Asthma & COPD Therapies Market 2017-2027

Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs

Product code: PHA0234

  • Publication date: 06/09/2017
  • Number of Pages: 300
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

The global asthma & COPD therapies market was valued at $32.9bn in 2016 and is projected to grow at a CAGR of 5.6% in the first half of the forecast period. The Anti-inflammatory Drugs submarket will be the fastest growing submarket in the first half of the forecast period. This submarket is estimated to grow at a CAGR of 7.6%.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 300-page report you will receive 113 tables and 130 figures – all unavailable elsewhere.

The 300-page report provides clear detailed insight into the global asthma & COPD therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
Global Asthma & COPD Therapies Market forecasts from 2017-2027, further broken down into:
- Global Asthma Therapies Market forecasts
- Global COPD Therapies Market forecasts

Revenue forecasts of the three main drug classes of the global asthma & COPD therapies market:
- Bronchodilators monotherapy
- Anti-inflammatory drugs
- Combination drugs

Revenue forecast for the Bronchodilators monotherapy market by Type and revenue forecast of the leading drugs:
- Short-acting beta2-agonists (SABAs): Ventolin, ProAir, Proventil, Xopenex
- Long-acting beta2-agonists (LABAs): Brovana, Foradil, Arcapta/Onbrez, Serevent,
- Anticholinergics: Spiriva, Atrovent, Eklira/Tudorza/Bretaris

Revenue forecast for the Anti-inflammatory drugs market by Type and revenue forecast of the leading drugs:
- Corticosteroids: Pulmicort, Flixotide/Flovent, QVAR, Asmanex
- Anti-leukotrienes: Singulair
- Monoclonal antibodies (mAbs): Xolair, Cinquil/Cinquair, Nucala, Benralizumab, Lebrikizumab, Dupilumab

Revenue forecast for the Combination drugs market and the leading drugs:
- Advair/Seretide, Symbicort, Combivent, Dulera, Relvar/Breo

• This report provides individual revenue forecasts from 2017-2027 for these regional and national markets:
- The US
- Japan
- EU5: Germany, France, UK, Italy, Spain
- BRIC: Brazil, Russia, India, China
- Mexico
- Other Countries

Global Asthma & COPD Therapies Market 2017-2027

• This report discusses the leading companies in the global asthma & COPD therapies market:
- GSK
- Boehringer Ingelheim
- AstraZeneca
- Novartis
- Merck
- Roche
- Teva

• This report discusses drugs currently in clinical development for treating asthma and COPD.

• This report discusses the SWOT analysis as well as porter’s five forces analysis of the global asthma & COPD therapies market.

Visiongain’s study is intended for anyone requiring commercial analyses for the global asthma & COPD therapies market. You find data, trends and predictions.

Buy our report today Global Asthma & COPD Therapies Market 2017-2027:
Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs
.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Table of Contents

1. Report Overview
1.1 Global Asthma and COPD Therapies Market Overview
1.2 Global Asthma and COPD Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Asthma and COPD Therapies
2.1 The Pharmaceutical Industry: A Very Brief Overview
2.2 Classifying Respiratory Diseases: Obstructive and Restrictive
2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive
2.3 What is Asthma?
2.3.1 Trends in Asthma Prevalence
2.3.2 Pathophysiology of Asthma
2.3.3 Symptoms of Asthma
2.3.4 Causes and Triggers for Asthma
2.3.5 Treatment of Asthma
2.3.6 Guidelines for Asthma Treatment
2.3.7 Drug Treatments for Asthma
2.3.8 Drug Delivery Methods in Asthma
2.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
2.4.1 Trends in COPD Prevalence
2.4.2 Pathophysiology of COPD
2.4.3 Signs and Symptoms of COPD
2.4.4 Treatment of COPD
2.4.5 Drug Treatments for COPD
2.4.6 Guidelines for COPD Treatment
2.5 Major Drug Classes in the Treatment of Asthma and COPD
2.5.1 Bronchodilators
2.5.2 Anti-Inflammatory Drugs
2.5.3 Combination Drugs
2.6 Phases of Clinical Trials
2.7 Scope of this Report

3. Asthma and COPD Therapies: Global Market 2016-2027
3.1 The Global Respiratory Drugs Market by Therapeutic Area
3.2 The Global Asthma and COPD Therapies Market in 2016
3.2.1 Leading Asthma and COPD Therapies
3.2.2 Leading Companies in the Asthma and COPD Therapies Market
3.3 Global Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2016-2027
3.3.1 Global Asthma Therapies Market: Sales Forecast, 2016-2027
3.3.2 Global COPD Therapies Market: Sales Forecast 2016-2027
3.4 Global Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2016-2027
3.5 Combination Drugs Lead the Asthma and COPD Therapies Market
3.6 How Will Segmental Shares Change to 2027
3.6.1 Global Asthma and COPD Therapies Market: Drivers and Restraints 2016-2027
3.7 Asthma and COPD Therapies: Trends and Developments
3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?

4. Bronchodilator Monotherapy Market 2016-2027
4.1 Introduction to Bronchodilator Monotherapy
4.2 The Bronchodilator Monotherapy Market in 2016
4.2.1 Leading Bronchodilators in 2016
4.2.2 Bronchodilator Monotherapy: Market Forecast 2016-2027
4.2.3 How Will Market Shares by Drug Class Change to 2027?
4.3 The Anticholinergics Market 2016-2027
4.3.1 Leading Anticholinergics in 2016
4.3.2 Anticholinergics: Market Forecast 2016-2027
4.3.3 Market Share of Leading Anticholinergics to 2027
4.3.4 Spiriva (tiotropium. Boehringer Ingelheim)
4.3.5 Atrovent (ipratropium, Boehringer Ingelheim)
4.3.6 Eklira/Tudorza/Bretaris (alcidinium, AstraZeneca/Menarini)
4.4 The SABAs Market 2017-2017
4.4.1 Leading SABAs in 2016
4.4.2 SABAs: Market Forecast 2016-2027
4.4.3 Market Share of Leading SABAs to 2027
4.4.4 Ventolin (salbutamol, GSK)
4.4.5 ProAir (salbutamol, Teva)
4.4.6 Proventil (salbutamol, Merck)
4.4.7 Xopenex (levosalbutamol, Dainippon Sumitomo)
4.5 The Long-Acting Beta2-Agonist (LABA) Market 2016-2027
4.5.1 Leading LABAs in 2016
4.5.2 LABAs: Market Forecast 2016-2027
4.5.3 Market Share of Leading LABAs to 2027
4.5.4 Foradil (formoterol, Merck/Novartis)
4.5.5 Brovana (arfomoterol, Dainippon Sumitomo)
4.5.6 Arcapta/Onbrez (indacaterol, Novartis)
4.5.7 Severent (salmeterol, GSK)

5. Anti-inflammatory Drugs Market 2016-2027
5.1 Introduction to Anti-Inflammatory Drugs
5.2 The Anti-Inflammatory Drugs Market in 2016
5.2.1 Leading Anti-Inflammatory Drugs in 2016
5.2.2 Anti-Inflammatory Drugs: Market Forecast 2016-2027
5.2.3 How Will Market Shares by Drug Class Change to 2027?
5.3 The Corticosteroids Market 2016-2027
5.3.1 Leading Corticosteroids in 2016
5.3.2 Corticosteroids: Market Forecast 2016-2027
5.3.3 Market Share of Leading Corticosteroids to 2027
5.3.4 Flixotide/Flovent (fluticasone propionate, GSK)
5.3.5 Pulmicort (budesonide, AstraZeneca)
5.3.6 QVAR (beclometasone, Teva)
5.3.7 Asmanex (mometasone, Merck)
5.4 The Anti-Leukotrienes Market 2016-2027
5.4.1 Leading Anti-Leukotrienes in 2016
5.4.2 Anti-Leukotrienes: Market Forecast 2016-2027
5.4.3 Market Share of Leading Anti-Leukotrienes to 2027
5.4.4 Singulair (montelukast, Merck)
5.5 The Monoclonal Antibodies Market 2016-2027
5.5.1 Monoclonal Antibodies: Market Forecast 2016-2027
5.5.2 Market Share of Leading Monoclonal Antibodies to 2027
5.5.3 Xolair (omalizumab, Novartis/Roche)
5.5.4 Cinquil/Cinquair (reslizumab, Teva)
5.5.5 Nucala (Mepolizumab, GSK)
5.5.6 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
5.5.7 Lebrikizumab (RG3637, Roche)
5.5.8 Dupilumab (REGN668, Regeneron/Sanofi)

6. Combination Drugs Market 2016-2027
6.1 Introduction to Combination Drugs
6.1.1 Leading Combination Drugs in 2016
6.1.2 Combination Drugs: Market Forecast 2016-2027
6.1.3 How Will Market Shares by Drug Change to 2027?
6.1.4 Advair/Seretide (fluticasone/salmeterol, GSK)
6.1.5 Symbicort (budesonide/formoterol fumarate, AstraZeneca)
6.1.6 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
6.1.7 Dulera (formoterol/mometasone, Merck)
6.1.8 Breo/Relvar Ellipta (vilanterol/fluticasone furoate, GSK)
6.2 Recently Launched Combination Drugs

7. Leading National Markets 2016-2027
7.1 Regional Breakdown of the Global Asthma and COPD Therapies Market
7.2 Global Asthma and COPD Therapies Market; Regional Forecasts 2016-2027
7.2.1 How Will Regional Market Shares Change to 2027?
7.2.2 National Breakdown of the Global asthma and COPD Therapies Market
7.2.3 Global Asthma and COPD Therapies Market: National Markets Forecast 2016-2027
7.2.4 How Will National Market Shares Change to 2027?
7.3 The US Asthma and COPD Therapies Market 2016-2027
7.3.1 The US Asthma and COPD Therapies Market Forecast 2016-2027
7.3.2 US Asthma and COPD Therapies Market Trends and Developments
7.4 Japanese Asthma and COPD Therapies Market 2016-2027
7.4.1 Japanese Asthma and COPD Therapies Market Forecast 2016-2027
7.4.2 Japanese Asthma and COPD Therapies Market: Trends and Developments
7.5 EU5 Asthma and COPD Therapies Market 2016-2027
7.5.1 German Asthma and COPD Therapies Market Forecast 2016-2027
7.5.2 French Asthma and COPD Therapies Market Forecast 2016-2027
7.5.3 UK Asthma and COPD Therapies Market Forecast 2016-2027
7.5.4 Italian Asthma and COPD Therapies Market Forecast 2016-2027
7.5.5 Spanish Asthma and COPD Therapies Market Forecast 2016-2027
7.5.6 EU5 Asthma and COPD Therapies Market: Trends and Developments
7.6 BRIC Asthma and COPD Therapies Market 2016-2027
7.6.1 Chinese Asthma and COPD Therapies Market Forecast 2016-2027
7.6.2 Chinese Asthma and COPD Therapies Market: Trends and Developments
7.6.3 Brazilian Asthma and COPD Therapies Market Forecast 2016-2027
7.6.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments
7.6.5 Indian Asthma and COPD Therapies Market Forecast 2016-2027
7.6.6 Indian Asthma and COPD Therapies Market: Trends and Developments
7.6.7 Russian Asthma and COPD Therapies Market Forecast 2016-2027
7.6.8 Russian Asthma and COPD Therapies Market: Trends and Developments
7.7 Mexican Asthma and COPD Therapies Market 2016-2027
7.7.1 Mexican Asthma and COPD Therapies Market Forecast 2016-2027
7.7.2 Mexican Asthma and COPD Therapies Market: Trends and Developments

8. Leading Companies in the Asthma and COPD Therapies Market
8.1 Asthma and COPD Therapies: Increasing Competition
8.2 Leading Companies in Asthma and COPD in 2016
8.3 Leading Companies: Market Forecast 2016-2027
8.4 How Will Leading Companies’ Market Shares Change to 2027?
8.5 GSK
8.5.1 GSK: Asthma and COPD Therapies
8.5.2 GSK: Sales Forecast 2016-2027
8.5.3 GSK: Products in Development
8.5.4 GSK: Recent Developments
8.6 Boehringer Ingelheim
8.6.1 Boehringer Ingelheim: Asthma and COPD Therapies
8.6.2 Boehringer Ingelheim: Sales Forecast 2016-2027
8.6.3 Boehringer Ingelheim: Asthma and COPD Product Development Ceased
8.6.4 Boehringer Ingelheim: Recent Developments
8.7 AstraZeneca
8.7.1 AstraZeneca: Asthma and COPD Therapies
8.7.2 AstraZeneca: Sales Forecast 2016-2027
8.7.3 AstraZeneca: Products in Development
8.7.4 AstraZeneca: Recent Developments
8.8 Merck & Co. (Merck)
8.8.1 Merck: Asthma and COPD Therapies
8.8.2 Merck: Sales Forecast 2016-2027
8.8.3 Merck: Products in Development
8.8.4 Merck: Recent Developments
8.9 Novartis
8.9.1 Novartis: Asthma and COPD Therapies
8.9.2 Novartis: Sales Forecast 2016-2027
8.9.3 Novartis: Products in Development
8.9.4 Novartis: Recent Developments
8.10 Roche
8.10.1 Roche: Asthma and COPD Therapies
8.10.2 Roche: Sales Forecast 2016-2027
8.10.3 Roche: Products in Development
8.11 Teva
8.11.1 Teva: Asthma and COPD Therapies
8.11.2 Teva: Sales Forecast 2016-2027
8.11.3 Teva: Products in Development
8.11.4 Teva: Recent Developments

9. Asthma and COPD Therapies Pipeline Analysis 2016-2027
9.1 A Strong Asthma and COPD Pipeline
9.2 The Bronchodilators Pipeline
9.2.1 Bronchodilators: Phase 3 Pipeline
9.3 The Anti-Inflammatory Drugs Pipeline
9.3.1 Anti-Inflammatory Drugs: Phase 3 Pipeline
9.4 The Combination Drugs Pipeline
9.4.1 Combination Drugs: Phase 3 Pipeline
9.5 Other Asthma and COPD Drugs Pipeline

10. Qualitative Analysis of the Asthma and COPD Therapies Market 2016-2027
10.1 SWOT Analysis of the Asthma and COPD Therapies Market
10.2 Strengths
10.2.1 Increasing Prevalence and Disease Burden
10.2.2 High Costs of Treatment
10.2.3 The Changing Perception of COPD
10.2.4 Patient Education: Understanding the Severity of Respiratory Disease
10.2.5 Lifecycle Management Strategies to Counter Patent Expiry
10.2.6 Advanced Inhaler Technologies to Counter Generic Erosion
10.2.7 Developments in Diagnostics
10.3 Weaknesses
10.3.1 Under-Diagnosis: the ‘Ghost Population’
10.3.2 Side-Effects of Drug Classes
10.3.3 Patent Cliff for Devices
10.3.4 Low Patient Adherence
10.3.5 Costing Pressures in both Developed and Emerging Markets
10.4 Opportunities
10.4.1 Patient Phenotyping and Personalised Medicine
10.4.2 A Strong R&D Pipeline
10.4.3 Ultra-Long-Acting Beta2-Agonists
10.4.4 Muscarinic Antagonists and Beta2-Agonists (MABAs)
10.4.5 Monoclonal Antibodies
10.4.6 LAMA/LABA Combinations
10.4.7 Opportunities in Telehealth
10.5 Threats
10.5.1 Patent Expiry and Generic Competition
10.5.2 Pharmacy Benefit Managers and Cost Control
10.5.3 The WISDOM Trial Could Reduce Steroid Use in COPD
10.6 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market
10.6.1 Rivalry among Competitors [Medium]
10.6.2 Threat of New Entrants [Medium]
10.6.3 Power of Suppliers [Medium]
10.6.4 Power of Buyers [High]
10.6.5 Threat of Substitutes [Low]

11. Conclusions
11.1 Asthma and COPD Therapies: A Maturing Market
11.2 The Global Asthma and COPD Therapies Market in 2016
11.3 Current Leading Asthma and COPD Therapies Segments
11.3.1 Leading Asthma and COPD Therapies
11.3.2 Leading Asthma and COPD Therapies Companies
11.4 Leading Regional and National Markets
11.5 Global Asthma and COPD Therapies Market Forecast 2016-2027
11.6 The Future of the Asthma and COPD Therapies Market
11.6.1 Growth in Anti-Inflammatory and Combination Drugs
11.6.2 Personalised Medicine
11.6.3 Unmet Needs in Asthma and COPD
11.7 Strategies for Growth in 2016-2027

Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

List of Tables
Table 2.1 Classification of Respiratory Diseases, 2016
Table 2.2 Causes of Asthma, 2016
Table 2.3 Triggers of Asthma, 2016
Table 2.4 Clinical Trial Phases
Table 3.1 World Respiratory Drugs Market: Revenues ($m) and Market Shares (%) by Therapeutic Area, 2016
Table 3.2 Top 10 Asthma and COPD Therapies: Revenue ($m) and Market Shares (%), 2016
Table 3.3 World Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 3.4 World Asthma Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 3.5 World COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 3.6 Global Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), by Drug Class, 2016-2027
Table 3.7 Market Shares (%) of Leading Asthma and COPD Therapies Market Segments, by Drug Class, 2016, 2021 and 2027
Table 4.1 Bronchodilator Monotherapy Market: Revenues ($m) and Market Shares (%) by Drug Class, 2016
Table 4.2 Leading Bronchodilators: Revenues ($m) and Market Shares (%), 2016
Table 4.3 Bronchodilator Monotherapy Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2016-2027
Table 4.4 Leading Anticholinergics: Revenues ($m) and Market Shares (%), 2016
Table 4.5 Anticholinergics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2016-2027
Table 4.6 Anticholinergics Market: Market Shares (%) by Drug, 2016, 2021 and 2027
Table 4.7 Boehringer Ingelheim: Spiriva Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.8 Boehringer Ingelheim: Atrovent Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.9 AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.10 Leading SABAs in 2016
Table 4.11 SABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2016-2027
Table 4.12 SABAs Market: Market Shares (%) by Drug, 2016, 2021 and 2027
Table 4.13 GSK: Ventolin Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.14 Teva: ProAir Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.15 Merck: Proventil Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.16 Dainippon Sumitomo: Xopenex Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.17 Leading LABAs: Revenues ($m) and Market Shares (%), 2016
Table 4.18 LABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2016-2027
Table 4.19 Leading LABAs: Market Shares (%) by Drug, 2016, 2021 and 2027
Table 4.20 Merck/Novartis: Foradil Revenue ($m), AGR (%) and CAGR (%),2016-2027
Table 4.21 Dainippon Sumitomo: Brovana Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.22 Novartis: Arcapta/Onbrez Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.23 GSK: Serevent Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.1 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2016
Table 5.2 Leading Anti-Inflammatory Drugs: Revenues ($m) and Market Shares (%), 2016
Table 5.3 Anti-Inflammatory Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2016-2027
Table 5.4 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2021 and 2027
Table 5.5 Leading Corticosteroids: Revenues ($m) and Market Shares (%), 2016
Table 5.6 Corticosteroids Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2016-2027
Table 5.7 Corticosteroids Market: Market Share (%) by Drug, 2016, 2021 and 2027
Table 5.8 GSK: Flixotide/Flovent Revenue ($m) and AGR (%), 2016-2027
Table 5.9 AstraZeneca: Pulmicort Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.10 Teva: QVAR Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.11 Merck: Asmanex Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.12 Leading Anti-Leukotrienes: Revenues ($m) and Market Shares (%), 2016
Table 5.13 Anti-Leukotrienes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2016-2027
Table 5.14 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2016, 2021 and 2027
Table 5.15 Merck: Singulair Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.16 Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2016-2027
Table 5.17 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2016, 2021 and 2027
Table 5.18 Novartis/Roche: Xolair Asthma Indication Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.19 Teva: Cinquil/Cinquair Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.20 GSK: Nucala Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.21 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.22 Roche: Lebrikizumab Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.23 Regeneron/Sanofi: Dupilumab Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.1 Leading Combination Drugs: Revenues ($m) and Market Share (%), 2016
Table 6.2 Combination Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2016-2027
Table 6.3 Combination Drugs Market: Market Shares (%) by Drug, 2016, 2021 and 2027
Table 6.4 GSK: Advair/Seretide Revenue ($m) and AGR (%), 2016-2027
Table 6.5 AstraZeneca: Symbicort Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.6 Boehringer Ingelheim: Combivent Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.7 Merck: Dulera Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.8 GSK: Relvar/Breo Revenue ($m), AGR (%) and CAGR (%), 2016-202
Table 7.1 World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by Region, 2016
Table 7.2 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2016-2027
Table 7.3 Market Shares (%) of Leading Regional Asthma and COPD Therapies Markets, 2016, 2021 and 2027
Table 7.4 World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by National Market, 2016
Table 7.5 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2027
Table 7.5 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2027 (continued)
Table 7.6 Market Shares (%) of Leading National Asthma and COPD Therapies Markets, 2016, 2021 and 2027
Table 7.7 US Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.8 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.9 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2027
Table 7.10 German Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.11 French Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.12 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.13 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.14 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.15 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2027
Table 7.16 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.17 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.18 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.19 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.20 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.1 Leading Asthma and COPD Drug Manufacturers: Asthma and COPD Drugs Revenue ($m), Market Share (%), 2016
Table 8.2 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m) and Market Shares (%), 2021 and 2027
Table 8.4 GSK: Overview, 2016
Table 8.5 GSK: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2016
Table 8.6 GSK: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2016-2027
Table 8.7 GSK: Asthma and COPD Therapies Pipeline, 2016
Table 8.8 Boehringer Ingelheim: Overview, 2016
Table 8.9 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2016
Table 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2016-2027
Table 8.11 AstraZeneca: Overview, 2016
Table 8.12 AstraZeneca: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2016
Table 8.13 AstraZeneca: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2016-2027
Table 8.14 AstraZeneca: Asthma and COPD Therapies Pipeline, 2016
Table 8.15 Merck: Overview, 2016
Table 8.16 Merck: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2016
Table 8.17 Merck: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2016-2027
Table 8.18 Novartis: Overview, 2016
Table 8.19 Novartis: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2016
Table 8.20 Novartis: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2016-2027
Table 8.21 Novartis: Asthma and COPD Therapies Pipeline, 2016
Table 8.22 Roche: Overview, 2016
Table 8.23 Roche: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2016-2027
Table 8.24 Teva: Overview, 2016
Table 8.25 Teva: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2016
Table 8.26 Teva: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2016-2027
Table 8.27 Teva: Asthma and COPD Therapies Pipeline, 2016

List of Figures
Figure 1.1 Global Asthma and COPD Therapies Market Segmentation Overview, 2016
Figure 2.1 Summary of GINA Guidance for Asthma Treatment, 2016
Figure 2.2 Summary of GOLD Guidance for COPD Treatment, 2016
Figure 3.1 World Respiratory Drugs Market: Revenues ($m) by Therapeutic Area, 2016
Figure 3.2 World Respiratory Drugs Market: Market Shares (%) by Therapeutic Area, 2016
Figure 3.3 Top 10 Asthma and COPD Therapies: Market Shares (%), 2016
Figure 3.4 World Asthma and COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 3.5 World Asthma Therapies Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 3.6 World COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 3.7 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2016
Figure 3.8 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2021
Figure 3.9 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2027
Figure 3.10 World Asthma and COPD Therapies Market: Drivers and Restraints, 2016-2027
Figure 4.1 Bronchodilator Monotherapy Market: Revenues ($m) by Drug Class, 2016
Figure 4.2 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2021
Figure 4.3 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2027
Figure 4.4 Bronchodilator Monotherapy Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.5 Anticholinergics Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.6 Anticholinergics Market: Market Shares (%) by Drug, 2016
Figure 4.7 Anticholinergics Market: Market Shares (%) by Drug, 2021
Figure 4.8 Anticholinergics Market: Market Shares (%) by Drug, 2027
Figure 4.9 Boehringer Ingelheim: Spiriva Revenue ($m) and AGR (%), 2016-2027
Figure 4.10 Boehringer Ingelheim: Atrovent Revenue ($m) and AGR (%), 2016-2027
Figure 4.11 AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m) and AGR (%), 2016-2027
Figure 4.12 SABAs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.13 SABAs Market: Market Shares (%) by Drug, 2016
Figure 4.14 SABAs Market: Market Shares (%) by Drug, 2021
Figure 4.15 SABAs Market: Market Shares (%) by Drug, 2027
Figure 4.16 GSK: Ventolin Revenue ($m) and AGR (%), 2016-2027
Figure 4.17 Teva: ProAir Revenue ($m) and AGR (%), 2016-2027
Figure 4.18 Merck: Proventil Revenue ($m) and AGR (%), 2016-2027
Figure 4.19 Dainippon Sumitomo: Xopenex Revenue ($m) and AGR (%), 2016-2027
Figure 4.20 LABAs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.21 LABAs Market: Market Shares (%) by Drug, 2016
Figure 4.22 LABAs Market: Market Shares (%) by Drug, 2021
Figure 4.23 LABAs Market: Market Shares (%) by Drug, 2027
Figure 4.24 Merck/Novartis: Foradil Revenue ($m) and AGR (%), 2016-2027
Figure 4.25 Dainippon Sumitomo: Brovana Revenue ($m) and AGR (%), 2016-2027
Figure 4.26 Novartis: Arcapta/Onbrez Revenue ($m) and AGR (%), 2016-2027
Figure 4.27 GSK: Serevent Revenue ($m) and AGR (%), 2016-2027
Figure 5.1 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2016
Figure 5.2 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2016
Figure 5.3 Anti-Inflammatory Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.4 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2021
Figure 5.5 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2021
Figure 5.6 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2027
Figure 5.7 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2027
Figure 5.8 Corticosteroids Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.9 Corticosteroids Market: Market Share (%) by Drug, 2016
Figure 5.10 Corticosteroids Market: Market Share (%) by Drug, 2021
Figure 5.11 Corticosteroids Market: Market Share (%) by Drug, 2027
Figure 5.12 GSK: Flixotide/Flovent Revenue ($m) and AGR (%), 2016-2027
Figure 5.13 AstraZeneca: Pulmicort Revenue ($m) and AGR (%), 2016-2027
Figure 5.14 Teva: QVAR Revenue ($m) and AGR (%), 2016-2027
Figure 5.15 Merck: Asmanex Revenue ($m) and AGR (%), 2016-2027
Figure 5.16 Anti-Leukotrienes Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.17 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2016
Figure 5.18 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2021
Figure 5.19 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2027
Figure 5.20 Merck: Singulair Revenue ($m) and AGR (%), 2016-2027
Figure 5.21 Monoclonal Antibodies Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.22 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2021
Figure 5.23 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2027
Figure 5.24 Novartis/Roche: Xolair Asthma Indication Revenue ($m) and AGR (%), 2016-2027
Figure 5.25 Teva: Cinquil/Cinquair Revenue ($m) and AGR (%), 2016-2027
Figure 5.26 GSK: Nucala Revenue ($m) and AGR (%), 2016-2027
Figure 5.27 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m) and AGR (%), 2016-2027
Figure 5.28 Roche: Lebrikizumab Revenue ($m) and AGR (%), 2016-2027
Figure 5.29 Regeneron/Sanofi: Dupilumab Revenue ($m) and AGR (%), 2016-2027
Figure 6.1 Combination Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.2 Combination Drugs Market: Market Shares (%) by Drug, 2016
Figure 6.3 Combination Drugs Market: Market Shares (%) by Drug, 2021
Figure 6.4 Combination Drugs Market: Market Shares (%) by Drug, 2027
Figure 6.5 GSK: Advair/Seretide Revenue ($m) and AGR (%), 2016-2027
Figure 6.6 AstraZeneca: Symbicort Revenue ($m) and AGR (%), 2016-2027
Figure 6.7 Boehringer Ingelheim: Combivent Revenue ($m) and AGR (%), 2016-2027
Figure 6.8 Merck: Dulera Revenue ($m) and AGR (%), 2016-2027
Figure 6.9 GSK: Relvar/Breo Revenue ($m) and AGR (%), 2016-2027
Figure 7.1 World Asthma and COPD Therapies Market: Revenues ($m) by Region, 2016
Figure 7.2 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2016
Figure 7.3 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Region, 2016-2027
Figure 7.4 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2021
Figure 7.5 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2027
Figure 7.6 World Asthma and COPD Therapies Market: Revenues ($m) by National Market, 2016
Figure 7.7 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2016
Figure 7.8 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2021
Figure 7.9 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2027
Figure 7.10 US Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 7.11 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 7.12 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2016-2027
Figure 7.13 German Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 7.14 French Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 7.15 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and 2016-2027
Figure 7.16 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 7.17 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 7.18 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2016-2027
Figure 7.19 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 7.20 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 7.21 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 7.22 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 7.23 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 8.1 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), 2016
Figure 8.2 Leading Asthma and COPD Drug Manufacturers: Market Share (%), 2016
Figure 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2021
Figure 8.4 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2021
Figure 8.5 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2027
Figure 8.6 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2027
Figure 8.7 GSK: Asthma and COPD Therapies Revenue ($m) by Drug, 2016
Figure 8.8 GSK: Asthma and COPD Therapies Revenue Share (%) by Drug, 2016
Figure 8.9 GSK: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2016-2027
Figure 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) by Drug, 2016
Figure 8.11 Boehringer Ingelheim: Asthma and COPD Therapies Revenue Share (%) by Drug, 2016
Figure 8.12 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2016-2027
Figure 8.13 AstraZeneca: Asthma and COPD Therapies Revenue ($m) by Drug, 2016
Figure 8.14 AstraZeneca: Asthma and COPD Therapies Revenue Share (%) by Drug, 2016
Figure 8.15 AstraZeneca: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2016-2027
Figure 8.16 Merck: Asthma and COPD Therapies Revenue ($m) by Drug, 2016
Figure 8.17 Merck: Asthma and COPD Therapies Revenue Share (%) by Drug, 2016
Figure 8.18 Merck: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2016-2027
Figure 8.19 Novartis: Asthma and COPD Therapies Revenue ($m) by Drug, 2016
Figure 8.20 Novartis: Asthma and COPD Therapies Revenue Share (%) by Drug, 2016
Figure 8.21 Novartis: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2016-2027
Figure 8.22 Roche: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2016-2027
Figure 8.23 Teva: Asthma and COPD Therapies Revenue ($m) by Drug, 2016
Figure 8.24 Teva: Asthma and COPD Therapies Revenue Share (%) by Drug, 2016
Figure 8.25 Teva: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2016-2027
Figure 10.1 Asthma and COPD Therapies Market: Strengths and Weaknesses, 2016-2027
Figure 10.2 Asthma and COPD Therapies Market: Opportunities and Threats, 2016-2027
Figure 10.3 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market, 2016-2027
Figure 12.1 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Therapeutic Area, 2016-2027

Companies Listed

3M Drug Delivery Systems
AB Science
Actavis
Alcon
Alembic
Allen and Hanburys
Allergan
Almirall
Apotex
Ario Pharma
Array BioPharma
Aspen Pharmacare
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Bellephron
Ben Vue Laboratories
BioWa
BioXpress Therapeutics
Boehringer Ingelheim
Breath Limited
Bristol-Meyer Squibbs
Catalent Pharma Solutions
Cephalon
Ception Therapeutics
Chiesi Pharmaceuticals
Ciba-Geigy
Cipla
Circassia Pharmaceuticals
CVS Caremark
Daewoong Pharmaceutical
Dainippon Sumimoto
Dr. Reddy’s Laboratories
Express Scripts
Forest Pharmaceuticals
Fountain Biopharma
Genentech (Roche)
Grifols
GSK
Hikma Pharmaceuticals
Ikaria
Invion
Kamada
Kyorin Pharmaceuticals
Kyowa Hakko Kirin
Lilly
Mariposa
MedicNova
Medimmune
Menarini
Merck & Co.
Mylan
Novartis
Nycomed
Omega Pharma
Orion Pharmaceuticals
Pearl Therapeutics
Perrigo
Pfizer
Prosonix
Reckitt Becnkiser
Regeneron
Roche
Roxane Laboratories
Sandoz (Novaris)
Sanofi
Schering-Plough’s
SkyePharma
Sofotec
Stempeutics
Sunovion Pharmaceuticals
Synairgen
Takeda Pharmaceuticals
Tanox
Teva
Theravance
Vectura
Viatris
Watson (Actavis)

Organisations Mentioned in the Report
American Lung Association
Bank of Spain
Bundesministerium fur Gesundheit (German Ministry of Health)
Brazilian Unified Health System (SUS)
Department of Pharmaceuticals (India)
European Lung Foundation
European Respiratory Foundation
European Respiratory Society
Federal Commission for the Protection against Sanitary Risk (COFEPRIS)
Global Initiative for Asthma (GINA)
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
Italian Medicines Agency (AIFA)
Italian Servicio Sanitario Nazionale (SSN)
Japanese Pharmaceuticals and Medical Devices Agency
Pan-American Health Organization (PAHO)
Seguro Popular (Mexico)
UK National Health Service (NHS)
US Centers For Disease Control and Prevention (CDC)
US Food and Drug Administration (FDA)
US Institutes of Health
US National Blood, Heart and Lung Institute
World Health Organization (WHO)

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close